Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence.

[1]  O. Brawley,et al.  Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. , 1996, Acta oncologica.

[2]  O. Sartor,et al.  A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer : toxicity and response , 1996, Cancer Chemotherapy and Pharmacology.

[3]  E. Small,et al.  The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer , 1995, Cancer.

[4]  O. Dalesio,et al.  MAXIMUM ANDROGEN BLOCKADE IN ADVANCED PROSTATE-CANCER - AN OVERVIEW OF 22 RANDOMIZED TRIALS WITH 3283 DEATHS IN 5710 PATIENTS , 1995 .

[5]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[6]  P. Schellhammer,et al.  A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. , 1995, Urology.

[7]  P. Scardino,et al.  Screening for prostate cancer: An analysis of the early experience , 1995, CA: a cancer journal for clinicians.

[8]  O. Sartor,et al.  Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. , 1995, The American journal of medicine.

[9]  E. Crawford,et al.  Case Reports: Withdrawal Phenomenon With the Antiandrogen Casodex , 1995 .

[10]  P. Nieh.  Withdrawal phenomenon with the antiandrogen casodex. , 1995, The Journal of urology.

[11]  F. S. French,et al.  Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. , 1995, Molecular endocrinology.

[12]  I. Thompson,et al.  Southwest Oncology Group strategies in prostatic carcinoma. , 1995, Seminars in surgical oncology.

[13]  P. Wingo,et al.  Cancer statistics, 1995 , 1995, CA: a cancer journal for clinicians.

[14]  J. Moul,et al.  Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.

[15]  P. Carroll,et al.  Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. , 1994, Urology.

[16]  S. Steinberg,et al.  Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. , 1994, Journal of the National Cancer Institute.

[17]  K. Fischbeck,et al.  Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer. , 1994, Biochemical and biophysical research communications.

[18]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[19]  J. Veldscholte,et al.  Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  H. Wiley,et al.  Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. , 1993, The Journal of clinical endocrinology and metabolism.

[21]  N. Sato,et al.  Androgen receptor gene mutations in human prostate cancer , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  M. Koutsilieris,et al.  Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. , 1993, The Journal of urology.

[23]  H. Scher,et al.  Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Sylvester,et al.  Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. , 1993, Urology.

[25]  H. Scher,et al.  Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. , 1993, The Journal of urology.

[26]  E. Crawford.  Challenges in the management of prostate cancer. , 1992, British journal of urology.

[27]  E. Wilson,et al.  Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. , 1992, The Journal of biological chemistry.

[28]  E. Hammond,et al.  Long-term follow-up after radical prostatectomy. Identification of prognostic variables. , 1991, The Urologic clinics of North America.

[29]  B. O’Malley,et al.  Steroid hormone receptors and In vitro transcription , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[30]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[31]  P. Goodman,et al.  Leuprolide With and Without Flutamide in Advanced Prostate Cancer , 1990, Cancer.

[32]  R. Miesfeld,et al.  Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. , 1990, Molecular endocrinology.

[33]  J. Isaacs,et al.  Role of calcium in the programmed death of rat prostatic glandular cells , 1990, The Prostate.

[34]  R. Tjian,et al.  Synergistic activation by the glutamine-rich domains of human transcription factor Sp1 , 1989, Cell.

[35]  N. Kyprianou,et al.  Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death , 1989 .

[36]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[37]  J. Fiet,et al.  Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). , 1989, The New England journal of medicine.

[38]  C. Olsson,et al.  Induction of the TRPM-2 gene in cells undergoing programmed death , 1989, Molecular and cellular biology.

[39]  M. Beato.  Gene regulation by steroid hormones , 1989, Cell.

[40]  N. Kyprianou,et al.  Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration , 1989, The Prostate.

[41]  M. Chen,et al.  Aberrant response in vitro of hormone‐responsive prostate cancer cells to antiandrogens , 1989, The Prostate.

[42]  N. Kyprianou,et al.  Activation of programmed cell death in the rat ventral prostate after castration. , 1988, Endocrinology.

[43]  N. Kyprianou,et al.  Activation of a Ca2+−Mg2+‐dependent endonuclease as an early event in castration‐induced prostatic cell death , 1988, The Prostate.

[44]  C. Labrie,et al.  Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. , 1987, Journal of steroid biochemistry.

[45]  M. Tenniswood,et al.  Characterization and cloning of androgen-repressed mRNAs from rat ventral prostate. , 1987, Biochemical and biophysical research communications.

[46]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[47]  F. Labrie,et al.  Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. , 1985, Journal of steroid biochemistry.

[48]  P. Poyet,et al.  Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate , 1985, Molecular and Cellular Endocrinology.

[49]  H. Withers,et al.  Radiation biology in cancer research , 1980 .

[50]  D. Byar.  The veterans administration cooperative urological research group's studies of cancer of the prostate , 1973, Cancer.

[51]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[52]  D. Byar,et al.  Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate , 1970, Cancer.

[53]  D. Byar,et al.  Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo , 1970, Cancer.